FDA Refers Zonisamide, Bupropion, and Sevelamer to National Institutes of Health Foundation for Pediatric Studies

Summary

The US Food and Drug Administration (FDA) has referred three medications - ZONEGRAN (Zonisamide), WELLBUTRIN and ZYBAN (Bupropion), and RENAGEL (Sevelamer) - to the Foundation for the National Institutes of Health (NIH) Foundation for pediatric clinical trials, following a referral on November 14, 2003.